Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 17, 2019

Primary Completion Date

September 25, 2023

Study Completion Date

September 25, 2023

Conditions
Select Advanced Solid Tumors
Interventions
DRUG

IMC-C103C

Weekly IV infusions

DRUG

Atezolizumab

IV infusions every 3 weeks

DRUG

IMC-C103C

Weekly subcutaneous Injection

Trial Locations (19)

8035

Hospital Universitario Vall d'Hebron, Barcelona

10065

Memorial Sloan Kettering Cancer Center, New York

15213

UPMC Cancer Center, Pittsburgh

19107

Thomas Jefferson University Hospital, Philadelphia

28027

Clinica Universidad Navarra, Madrid

28046

Hospital Universitario La Paz - PPDS, Madrid

31008

Clinica Universidad Navarra, Pamplona

37203

Sarah Cannon Research Institute at Tennessee Oncology, Nashville

60637

The University of Chicago Medicine & Biological Sciences, Chicago

73104

Oklahoma University Medical Center, Oklahoma City

77030

MD Anderson Cancer Center, Houston

80045

University of Colorado Cancer Center, Aurora

90025

The Angeles Clinic and Research Institute, Los Angeles

95817

University of California Davis Comprehenvise Cancer Center, Sacramento

G12 OYN

Beatson West of Scotland Cancer Centre, Glasgow

CH634JY

The Clatterbridge Hospital Cancer Center, Bebington

W1G 6AD

Sarah Cannon Research Institute, London

M20 4BX

The Christie NHS Foundation Trust, Manchester

SM2 5PT

Royal Marsden Hospital, Sutton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Immunocore Ltd

INDUSTRY